Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity: oral: A K1, GLP-compliant acute oral toxicity test was performed in female Wistar rats according to the OECD guideline 420 and EU Method B.1 bis (Sanders, 2014a). The LD50 for the oral route was determined to be greater than 2000 mg/kg bw (equivalent to 1000 mg/kg bw of active ingredient). The commercial product, containing a 50% solution, doesn’t need to be classified on the basis of the available data.
Acute toxicity: inhalation: An acute inhalation study does not need to be conducted as acute oral and acute dermal toxicity studies are available, according to Column 2 adaptations in the REACH regulation.
Acute toxicity: dermal: A K1, GLP-compliant acute dermal toxicity test was performed in male and female Wistar rats according to OECD guideline 402 and EU Method B.3 (Sanders, 2015). The LD50 for the dermal route was determined to be greater than 4000 mg/kg bw (equivalent to 2000 mg/kg bw of active ingredient). No classification is needed.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Acute toxicity: oral:
Sanders (2014a) investigated the acute oral toxicity of the 50% solution of the substance via gavage of 300 and 2000 mg/kg bw in 6 female Wistar rats (1 animal in the 300 mg/kg dose group and 5 animals in the 2000 mg/kg dose group) (K1, GLP). There were no deaths observed. No signs of systemic toxicity were noted during the observation period. All animals showed expected gains in body weight over the observation period and no abnormalities were noted at necropsy. The acute oral LD50 was determined to be greater than 2000 mg/kg bw (equivalent to 1000 mg/kg bw of active ingredient).
Acute toxicity: inhalation:
No reliable studies were available for the inhalation route. An acute inhalation study does not need to be conducted as acute oral and acute dermal toxicity studies are available, according to Column 2 adaptations in the REACH regulation.
Acute toxicity: dermal:
Sanders (2015) investigated the acute dermal toxicity of the substance in 5 male and 5 female Wistar rats after 24 hours of exposure to 4000 mg/kg bw of the test substance (equivalent to 2000 mg active ingredient/kg bw) (K1, GLP). There were no deaths observed. No signs of systemic toxicity were noted during the observation period. There were no signs of dermal irritation. Animals showed expected gains in body weight, except for two females which showed body weight loss during the first week but expected body weight gain during the second week. No abnormalities were observed at necropsy. After 14 days of observation, the dermal LD50 was determined to be greater than 4000 mg test substance/kg bw (equivalent to 2000 mg/kg bw of active ingredient).
Justification for selection of acute toxicity – oral endpoint : Only one reliable study available.
Justification for selection of acute toxicity – inhalation endpoint : No reliable studies were available for the inhalation route. An acute inhalation study does not need to be conducted as acute oral and acute dermal toxicity studies are available, according to Column 2 adaptations in the REACH regulation.
Justification for selection of acute toxicity – dermal endpoint : Only one reliable study available.
Justification for classification or non-classification
Based on the results of the acute oral and acute dermal toxicity study and according to the criteria of the CLP Regulation, the commercial product, containing a 50% solution, doesn't need to be classified on the basis of the available data.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.